U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula O4P
Molecular Weight 95.9715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge -3

SHOW SMILES / InChI
Structure of PHOSPHATE ION P-32

SMILES

O=P([O-])([O-])[O-]

InChI

InChIKey=NBIIXXVUZAFLBC-HOSYLAQJSA-K
InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3/i5+1

HIDE SMILES / InChI
P-32 is a radioactive isotope of phosphorus with a half-life of 14.29 days. Radioactive decay of P-32 produces beta-particles (electrons) which are able to penetrate tissue at a range of 3-8 mm. Phosphate ion P-32 has many applications in medicine and biology. P32 sodium phosphate was approved by the FDA for the treatment of polycythemia vera, chronic myelocytic leukemia, and chronic lymphocytic leukemia. P32-phosphate may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases. As metabolic uptake of phosphorus is selectively increased in malignant tissues, P-32 was also used for cancer diagnostics.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

-3.41884797E11
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

-3.41884797E11
Primary
SODIUM PHOSPHATE P 32

Approved Use

P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases

Launch Date

-3.41884797E11
PubMed

PubMed

TitleDatePubMed
EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases.
2007 Aug
Name Type Language
PHOSPHATE ION P-32
Common Name English
Classification Tree Code System Code
NDF-RT N0000000205
Created by admin on Sat Jun 26 07:39:20 UTC 2021 , Edited by admin on Sat Jun 26 07:39:20 UTC 2021
NDF-RT N0000175872
Created by admin on Sat Jun 26 07:39:20 UTC 2021 , Edited by admin on Sat Jun 26 07:39:20 UTC 2021
Code System Code Type Description
PUBCHEM
167704
Created by admin on Sat Jun 26 07:39:20 UTC 2021 , Edited by admin on Sat Jun 26 07:39:20 UTC 2021
PRIMARY
FDA UNII
N27ADP50ER
Created by admin on Sat Jun 26 07:39:20 UTC 2021 , Edited by admin on Sat Jun 26 07:39:20 UTC 2021
PRIMARY
DRUG BANK
DB14573
Created by admin on Sat Jun 26 07:39:20 UTC 2021 , Edited by admin on Sat Jun 26 07:39:20 UTC 2021
PRIMARY